Skip to main content
. Author manuscript; available in PMC: 2025 Dec 24.
Published in final edited form as: Blood. 2025 Feb 13;145(7):748–764. doi: 10.1182/blood.2022019306

Figure 3. Sequential pharmacological BET-followed by p300-inhibition counteracts expression of rescued programs.

Figure 3

A.-D. Left panels - Volcano plots showing RNASeq expression changes in the indicated cell lines after 24h of treatment with DMSO or p300i. Middle panels - Dot plots of GSEA normalized enrichment scores (NES) and FDRq significance of the top-scoring data sets after treatment with either DMSO or p300i for 24h in the indicated cell lines. Right panels - Analysis of qPCR expression of MYC and BCL2 in the indicated AML cell lines after treatment with either DMSO (48h of treatment), BETi (48h), p300i (24h) or sequential BETi and p300i (48h/24h). Shown are log2 Fold Changes normalized to DMSO-treated controls and SD from 3 biological replicates.

E. Analysis of qPCR expression of the indicated transcripts/genes in SKNO1 cells after treatment with either DMSO (48h of treatment), BETi (48h), p300i (24h) or sequential BETi and p300i (48h/24h). Shown are log2 Fold Changes normalized to DMSO-treated controls and SD from 3 biological replicates.